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Serum Amyloid A Stimulates PKR Expression and HMGB1
Release Possibly through TLR4/RAGE Receptors
Wei Li,1,2* Shu Zhu,1,2* Jianhua Li,2 Jason D’Amore,1 John D’Angelo,1 Huan Yang,2 Ping Wang,2
Kevin J Tracey,2 and Haichao Wang1,2
1

Department of Emergency Medicine, North Shore University Hospital, Manhasset, New York, United States of America; and 2The
Feinstein Institute for Medical Research, Manhasset, New York, United States of America

Serum amyloid A (SAA) proteins are known to be surrogate markers of sepsis, but their pathogenic roles remain poorly elucidated. Here we provide evidence to support a possible role of SAA as a pathogenic mediator of lethal sepsis. In a subset of septic patients for which serum high mobility group box 1 (HMGB1) levels paralleled the clinical scores, some anti-HMGB1 antibodies
detected a 12-kDa protein belonging to the SAA family. In contrast to the most abundant SAA1, human SAA induced doublestranded RNA-activated protein kinase R (PKR) expression and HMGB1 release in the wild-type, but not toll-like receptor 4/receptor for advanced glycation end products (TLR4/RAGE)-deficient, macrophages. Pharmacological inhibition of PKR phosphorylation blocked SAA-induced HMGB1 release, suggesting an important role of PKR in SAA-induced HMGB1 release. In animal
models of lethal endotoxemia and sepsis, recombinant SAA exacerbated endotoxemic lethality, whereas SAA-neutralizing immunoglobulins G (IgGs) significantly improved animal survival. Collectively, these findings have suggested SAA as an important
mediator of inflammatory diseases. Highlights of this study include: human SAA is possibly only expressed in a subset of septic patients; SAA induces HMGB1 release via TLR4 and RAGE receptors; SAA supplementation worsens the outcome of lethal endotoxemia; whereas SAA-neutralizing antibodies confer protection against lethal endotoxemia and sepsis.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2015.00109

INTRODUCTION
Despite recent advances in antibiotic
therapy and intensive care, sepsis remains a significant problem in critically
ill patients with >225,000 victims in the
U.S. alone. The pathogenesis of sepsis remains poorly understood, but is attributable to dysregulated immune responses
orchestrated by innate immune cells including macrophages/monocytes (1).
Macrophages/monocytes are equipped
with various pattern recognition receptors (PRRs) (such as the toll-like receptors [TLRs] TLR2, TLR4 and TLR9),

which can recognize various pathogenassociated molecular patterns (PAMPs)
(such as bacterial lipoproteins, endotoxins and CpG-DNA) (2). Upon
PRR–PAMP engagement, innate immune
cells sequentially release early (for example, tumor necrosis factor [TNF], interleukin [IL]-1, interferon [IFN]-γ and coldinducible RNA-binding protein [CIRP])
(3,4) and late (for example, nitric oxide
[NO] or high mobility group box 1
[HMGB1]) proinflammatory mediators
(5,6). If dysregulated, the excessive release of these late mediators adversely
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contributes to the pathogenesis of lethal
sepsis (4,7–9).
In addition to stimulating macrophages/
monocytes to release late proinflammatory mediators, early cytokines also alter
the expression of liver-derived acutephase proteins that similarly participate
in the regulation of inflammatory responses. For instance, TNF, IL-1β and interferon (IFN)-γ induce the expression of
serum amyloid A (SAA) in hepatocytes
(10) and macrophages/monocytes (11),
resulting in subsequent SAA secretion
upon cleaving off the signal sequence.
The human SAA family is comprised of
multiple members, including the most
abundant SAA1, and other isoforms such
as SAA, SAA2α, SAA2β and SAA3.
Members of the SAA family share
>95–98% identity within species, with
>75% sequence homology between
human and rodents. During endotoxemia, circulating SAA levels are significantly elevated (up to 1,000-fold) within
16–24 h as a result of de novo expression
of early cytokine inducers and subse-
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quent synthesis and secretion of SAAs
(12,13). Clinically, SAAs have been implicated as biomarkers in cardiovascular
disorders (14), ulcerative colitis (15) and
sepsis (16). Extracellular SAA signals via
a family of receptors including the receptor for advanced glycation end products
(RAGE) (17), TLR2 (18,19) and TLR4 (20)
to activate NLRP3 inflammasome (21)
and to induce various cytokines and
chemokines (22–25).
Previously, we demonstrated that a
ubiquitous nuclear protein, HMGB1, is
released from macrophages/monocytes
in response to exogenous PAMPs (for example, lipopolysaccharide [LPS] and
CpG-DNA) (6,26) or endogenous cytokines (for example, IFN-γ or CIRP)
(4,27). The nucleus-to-cytoplasm translocation of HMGB1 is mediated by the
STAT1-mediated acetylation of the
HMGB1 nuclear-localization sequences
(28). The extracellular HMGB1 release is
regulated by caspase 1- and the doublestranded RNA-activated protein kinase
R (PKR)-dependent inflammasome activation (29,30), pyroptosis (31) or necroptosis (32). For instance, pharmacological
inhibition of PKR interaction with pyroptosome components (for example,
apoptosis-associated speck protein
[ASC]) by the 7-desacetoxy-6,7dehydrogedunin (7DG) (31) results in
the interruption of pyroptosis. Similarly,
the suppression of PKR-mediated phosphorylation of necrosome components
(for example, the death domain receptor–interacting protein 1 kinase [RIP1]
and RIP3) by kinase inhibitors (for example, C16) (32) leads to the impairment
of necroptosis. It was previously unknown, however, whether SAA can induce PKR expression to stimulate
HMGB1 release.
In this study, we report a possibility
that SAA was expressed only in a subset
of septic patients and stimulated the
expression of PKR and caused HMGB1
release in wild-type, but not in
TLR4/RAGE-deficient, macrophages.
Pharmacological inhibition of PKR
phosphorylation inhibited SAA-induced
HMGB1 release, and administration of

SAA-neutralizing immunoglobulins G
(IgGs) significantly improved animal
survival in sepsis. Collectively, these
findings have suggested a possible role
of SAA as an important mediator for
lethal inflammatory diseases.
MATERIALS AND METHODS
Materials
Crude bacterial endotoxin (LPS, E. coli
0111:B4; catalog no. L4130), mouse anti-βactin antibodies (catalog no. A1978) were
Sigma-Aldrich products. Calcein-AM (catalog no. C3099), CM-DiI (catalog no.
C7001), Dulbecco modified Eagle medium
(DMEM) (catalog no. 11995-065), penicillin/streptomycin (catalog no. 15140-122),
fetal bovine serum (FBS) (catalog no.
26140079) and Trypan blue (catalog no.
15250-061) were Invitrogen products.
Anti-PKR antibody (catalog no. sc-6282)
and horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (catalog no. sc2060) were Santa Cruz Biotechnology
products. Anti-phosphorylated PKR antibody (T451; catalog no. 07-886) was a Millipore product. Rabbit anti-p-STAT1
(Y701; catalog no. 7649S) was a Cell Signaling product. Rabbit anti-TLR9 (catalog
no. NBP1-76680) was a Novus Biologicals
product. Recombinant human SAA (catalog no. 300-13) and SAA1 (catalog no. 30053) were PeproTech products. HRP-conjugated donkey anti-rabbit IgG was a GE
Healthcare product (catalog no. NA934).
HMGB1-specific polyclonal antibodies
were generated in rabbits as previously
described (6). TLR2, TLR4 and RAGE KO
mice and TLR2/RAGE and TLR4/RAGEdouble KO mice on a C57BL/6 genetic
background were maintained at The Feinstein Institute for Medical Research as
previously described (33). SAA1/2 knockout mice were generated by targeted deletion of the exon 2 of both Saa1 and Saa2
genes as previously described (34), and
the knockout mice were backcrossed into
a C57BL/6 genetic background. Because
the KO mice were derived from C57BL/6
mice, small colonies of wild-type
C57BL/6 (The Jackson Laboratory) were
maintained under the same conditions.
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Preparation of Recombinant HMGB1
The cDNA encoding for rat HMGB1
was cloned onto a pCAL-n vector, and
the recombinant calmodulin-binding
protein (CBP)–tagged HMGB1
(rHMGB1) was expressed in E. coli BL21
(DE3) pLysS cells as previously described (6). The rHMGB1 containing an
~3-kDa CBP tag (CBP-HMGB1 fusion
protein, 33 kDa) was expressed in E. coli
and purified to remove contaminating
endotoxin by Triton X-114 extraction, as
previously described (35).
Cell Culture
Murine macrophage-like RAW 264.7
and human monocytic U937 cells were
obtained from the American Type Culture Collection (ATCC). Primary peritoneal macrophages were isolated from
Balb/C mice (Taconic; male, 7–8 wks,
20–25 g) at 2–3 d after intraperitoneal injection of 2 mL thioglycollate broth (4%),
as previously described (36,37). RAW
264.7 macrophages, U937 monocytes and
primary macrophages were cultured in
DMEM supplemented with 1% penicillin/streptomycin and 10% FBS. Adherent
macrophages or monocytes were gently
washed with, and cultured in, DMEM before stimulating with LPS (0.5 μg/mL),
HMGB1 (0.5 μg/mL) or human SAA, in
the absence or presence of PKR inhibitors
or SAA-neutralizing IgGs for 16 h. Subsequently, the cell-conditioned culture
media were analyzed respectively for levels of HMGB1, nitric oxide and other cytokines by Western blotting analysis, the
Griess reaction and cytokine antibodies
arrays as previously described (38,39).
Western Blotting
The levels of HMGB1 in the culture
medium were determined by Western
blotting analysis as previously described
(6,27). The levels of total PKR, phosphorylated PKR (P-PKR, T451) or phosphorylated STAT1 (P-STAT1, Y701) in primary macrophage lysates were
determined by Western blotting analysis
with reference to β-actin. Briefly, equal
amounts of cellular proteins were resolved on sodium dodecyl sulfate (SDS)-
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polyacrylamide gel electrophoresis
(PAGE) gels and transferred to
polyvinylidene difluoride membranes.
After blocking with 5% nonfat milk, the
membrane was incubated with respective antibodies overnight [anti-PKR,
1:250; anti-phospho-PKR (T451), 1:1,000;
anti-P-STAT1 (Y701), 1:500; anti-β-actin,
1:5,000]. Subsequently, the membrane
was incubated with the appropriate secondary antibody, and the immunoreactive bands were visualized by chemiluminescence technique.

the Department of Emergency Medicine,
North Shore University Hospital. The
American College of Chest Physicians/
Society of Critical Care Medicine Consensus Conference definitions of sepsis
and septic shock were used for the diagnosis of these patients (41). As controls,
blood samples (10 mL) were also collected from eight healthy individuals.
Serum samples were analyzed for levels
of HMGB1 and 42 other cytokines by
Western blotting and cytokine antibody
arrays, respectively.

Nitric Oxide Assay
The levels of NO in the culture medium were determined indirectly by
measuring the NO2– production with a
colorimetric assay on the basis of the
Griess reaction (36,40). NO2– concentrations were determined with reference to
a standard curve generated with sodium
nitrite at various dilutions.

MALDI-TOF Mass Spectrometry
To identify the 12-kDa band that crossreacted with anti-HMGB1 antibodies,
serum samples were resolved by SDSPAGE, and the corresponding 12-kDa
band was subjected to MALDI-TOF mass
spectrometry analysis. Briefly, the 12-kDa
band was excised from the SDS-PAGE gel
and subjected to in-gel trypsin digestion.
The mass of the tryptic peptides was
measured by matrix-assisted laser desorption/ionization–time of flight mass
spectrometer (MALDI-TOF-MS) and then
subjected to peptide mass fingerprinting
database analysis to identify the 12-kDa
protein (“P12”) in septic patients.

Cytokine Antibody Array
Human Cytokine Antibody Array C3
(catalog no. AAH-CYT-3-4) and Murine
Cytokine Antibody Arrays (catalog no.
M0308003, RayBiotech Inc., which respectively detect 42 and 62 cytokines on
one membrane, were used to determine
cytokine levels in human serum or cell
culture medium as previously described
(36,40). Briefly, the membranes were sequentially incubated with equal volumes
of human serum (10 μL, mixed with
90 μL buffer) or cell culture medium
(200 μL), primary biotin-conjugated
antibodies and horseradish peroxidase–
conjugated streptavidin. After exposing
to X-ray film, the relative signal intensity
was determined by using the Scion
Image software.
Clinical Characterization of Septic
Patients
As per the approval by the Feinstein
Institute for Medical Research institutional review board ethics committee,
blood samples (10 mL) were collected at
various time points (0, 12, 24, 48 and
72 h) after the diagnosis of patients with
septic shock, severe sepsis or sepsis, in

Analysis of Contaminating Bacterial
Products
The recombinant human SAA and
SAA1 were analyzed for contaminating
bacterial products (such as lipoproteins,
CpG-DNAs) by SDS-PAGE, followed by
Coomassie blue or ethidium bromide
staining. Recombinant HMGB1 protein
was used as a control for comparison.
Recombinant SAAs were tested for LPS
content by the chromogenic Limulus
amebocyte lysate assay (Endochrome;
Charles River), and the endotoxin content was expressed as nanograms endotoxin per microgram of SAAs.
Animal Models of Endotoxemia and
Polymicrobial Sepsis
This study was approved and performed in accordance with the guidelines
for the care and use of laboratory animals at the Feinstein Institute for Med-

ical Research, Manhasset, New York. To
evaluate the role of SAA in lethal sepsis,
Balb/C mice (male, 7–8 wks, 20–25 g)
were subjected to lethal endotoxemia or
sepsis induced by cecal ligation and
puncture (CLP) as previously described
(38,39,42). Briefly, the cecum of Balb/C
mice was ligated at 5.0 mm from the
cecal tip and then punctured once with a
22-gauge needle. Recombinant SAA or
SAA-neutralizing antibodies were intraperitoneally administered into endotoxemic or septic mice at indicated doses
and time points, and animal survival
rates were monitored for up to 2 wks.
Generation of Anti-SAA Polyclonal
Antibodies
Female New Zealand white rabbits
were repetitively immunized with recombinant human SAA in combination
with the Freund’s complete adjuvant,
and blood was collected on 3-wk cycles
of immunization and bleed. The antibody titers were determined by direct
SAA ELISA, and total IgGs were purified
from the serum using a Protein A affinity
column as previously described (6).
Briefly, rabbit serum was prebuffered
with PBS and slowly loaded to a protein
A column to allow sufficient binding of
IgGs. After washing with 1× PBS to remove nonbound serum components,
the IgGs were eluted with acidic buffer
(0.1 mol/L glycine-HCl, pH 2.8) and then
immediately dialyzed into 1× PBS buffer
at 4°C overnight.
Peptide Dot Blotting
A library of 19 overlapping peptides
(18-mer, offsite by 6) corresponding to the
human SAA sequence were synthesized
and spotted (1.0 μg in 2.5 μL) onto nitrocellulose membrane (Thermo Scientific,
catalog no. 88013). Subsequently, the
membrane was probed with IgGs from
different rabbits following a standard
protocol.
Statistical Analysis
Data are expressed as mean ± SEM of
two independent experiments in triplicates (n = 2). One-way analyses of vari-
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Figure 1. Identification of SAA as an anti-HMGB1 IgG cross-reacting protein in a subset of
septic patients. (A) Western blots of serum proteins. Note that certain polyclonal antiHMGB1 IgGs recognized both the 30-kDa HMGB1 and a 12-kDa protein (termed “P12”) in
a subset of septic patients. (B) Immunoassay of multiple cytokines and chemokines by cytokine antibody arrays. Note that the serum levels of several sepsis surrogate markers (IL-6,
MCP-1 and RANTES) paralleled with the clinical scores. *P < 0.05 versus normal healthy
controls; #P < 0.05 versus t = 0 h (diagnosis of septic shock). (C) Mass spectrometry analysis
of P12. The identity of the 12-kDa protein (P12) in septic serum was determined by mass
spectrometry after gel excision and in-gel trypsin digestion.

ance (ANOVAs) followed by the
Tukey’s test for multiple comparisons
were used to compare between different
groups. The Kaplan-Meier method was
used to compare the differences in mortality rates between groups. A P value
<0.05 was considered statistically
significant.
RESULTS
Identification of Human SAA, but not
SAA1, as an HMGB1 Inducer
To understand the role of cytokines in
sepsis, we characterized the kinetics of
circulating HMGB1 and other cytokines

in a group of septic patients admitted
to the Emergency Medicine Department
at North Shore University Hospital. In 8
of 23 septic patients, serum HMGB1
levels paralleled with the clinical
scores; circulating HMGB1 levels returned toward baseline when these patients recovered from septic shock or
severe sepsis (Figure 1A, data not
shown). In a subset of septic patients,
the anti-HMGB1 IgGs cross-reacted
with a 12-kDa protein (denoted as
“P12”) (Figure 1A), which paralleled
with the serum levels of HMGB1 (Figure 1A) and several sepsis biomarkers
(for example, IL-6, growth regulated
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oncogene-alpha/keratinocyte chemoattractant (GRO/KC), monocyte chemoattractant protein-1 (MCP-1) and regulated upon activation, normal T-cell
expressed and secreted (RANTES); Figure 1B). To uncover the possible role of
P12 in HMGB1 release, septic serum
proteins were resolved by SDS-PAGE,
and the corresponding 12-kDa band
was subjected to in-gel trypsin digestion and mass spectrometry analysis.
Peptide mass fingerprinting analysis
identified this protein as a member(s) of
the human SAA family (Figure 1C).
In agreement with the high homology
between human and murine SAAs (Figure 2A), polyclonal antibodies generated against human SAA cross-reacted
with both human SAA and SAA1 on
Western blots (Figure 2B, bottom panel).
Remarkably, the anti-HMGB1 IgGs that
detected the P12 in a subset of septic patients, also specifically recognized
human SAA, but not SAA1 (Figure 2B),
suggesting an antigenic distinction between human SAA and SAA1 despite
their high sequence homology (Figure
2A). Moreover, there is a dramatic difference in their biological activities. At
physiologically relevant concentrations
(0.1–10 μg/mL), human SAA effectively
stimulated murine macrophages and
human monocytes to release HMGB1
(Figure 2C) in a dose- and timedependent fashion (Figure 2D). In contrast, human SAA1 completely failed to
induce HMGB1 release even when
given at concentrations up to 10 μg/mL
(Figure 2C). Recombinant SAA and
SAA1 were not contaminated with
bacterial lipoproteins or CpG-DNA (Figure 2E) and occasionally contained low
levels of endotoxins (Figure 2F). This
trivial endotoxin contamination was not
likely the underlying cause for SAAmediated HMGB1 release, because endotoxin-neutralizing agents (for example, polymyxin B) failed to impair
SAA-induced HMGB1 release (data not
shown). Furthermore, many SAA preparations that were totally free from endotoxin contamination could still effectively induce HMGB1 release.
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Figure 2. Human SAA, but not SAA1, induced HMGB1 release. (A) Amino acid sequence of human and murine SAAs. Bar (|), identical
residues; colon (:), homologous residues. The bold letters denote the two residues that distinguish between human SAA and SAA1.
(B) Western blots of human SAA and SAA1. Note that the anti-HMGB1 IgGs that recognized the P12 in septic patients also specifically
cross-reacted with huSAA, but not huSAA1. (C) HuSAA, but not huSAA1, induced HMGB1 release. Murine RAW 264.7 macrophages and
human U937 monocytes were stimulated with huSAA or huSAA1 for 16 h, and extracellular HMGB1 levels were determined by Western
blots. (D) Dose-response and time course of SAA-induced HMGB1 release. RAW 264.7 macrophages were stimulated with huSAA at indicated doses and for indicated time periods, and extracellular HMGB1 levels were determined by Western blotting analysis by using monoclonal anti-HMGB1 antibody. (E) Detection of bacterial lipoproteins and DNAs by gel electrophoresis. Large amounts of SAAs and
rHMGB1 were resolved on SDS-PAGE and stained with Coomassie blue or ethidium bromide to detect contaminating bacterial lipoprotein or DNA. (F) LAL endotoxin assay. Four separate batches of recombinant huSAA and huSAA1 were assayed for endotoxin content.
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Figure 3. Distinct roles of TLR4 and RAGE receptors in SAA-induced cytokines/chemokines,
NO and HMGB1. Thioglycollate-elicited primary macrophages were isolated from wildtype or mutant mice respectively deficient in TLR2, TLR4, RAGE, TLR2/RAGE or TLR4/RAGE.
After stimulation with huSAA (0.5 μg/mL) for 16 h, the extracellular levels of cytokines,
chemokines, NO and HMGB1 were determined by cytokine antibody arrays (A), Griess reaction (B) and Western blotting (C), respectively. The disruption of TLR4 completely abolished SAA-induced NO production, and partly impaired several cytokines/chemokines,
but did not affect SAA-induced HMGB1 release. The concurrent knockout of both TLR4
and RAGE completely abrogated SAA-induced HMGB1 release (C). *P < 0.05 versus –SAA
controls; #P < 0.05 versus WT + SAA.

Requirement of TLR4/RAGE Receptors
in SAA-Induced HMGB1 Release
SAAs can signal via multiple receptors
including the TLR2, TLR4 (18–20,43) and
RAGE (17,25) to activate macrophages
and monocytes. To identify the receptor(s)
responsible for SAA-mediated HMGB1
release, we compared the levels of SAAinduced HMGB1 release between primary
peritoneal macrophages from wild-type
and mutant mice, respectively, deficient in
TLR2, TLR4, RAGE, TLR2/RAGE or
TLR4/RAGE. We found that human SAA
effectively induced the release of cytokines (for example, IL-6 and IL-12),
chemokines (for example, MCP-1 and
RANTES) and NO (Figures 3A, B). Surprisingly, the disruption of TLR2, RAGE
or TLR2/RAGE did not obviously impair
SAA-induced cytokines/chemokines (Figure 3A), NO (Figure 3B) and HMGB1 re-

lease (Figure 3C). In contrast, the knockout of TLR4 partially impaired SAA-induced cytokines/chemokines (for example, IL-6, IL-12, MCP-1 and RANTES)
(Figure 3A) and completely abolished
SAA-induced NO production (Figure 3B).
However, the disruption of TLR4 alone
did not impair SAA-induced HMGB1 release, indicating the involvement of distinct signaling pathways in NO production and HMGB1 release. Deletion of both
TLR4 and RAGE resulted in an almost
complete impairment of HMGB1 release
(Figure 3C), indicating a critical requirement for both TLR4 and RAGE in SAAinduced HMGB1 release.
Requirement of TLR4/RAGE Receptors
for SAA-Induced PKR Upregulation
Emerging evidence has revealed an important role for PKR (30) and STAT1 (28)
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in LPS-induced HMGB1 release. To evaluate this mechanism of SAA-mediated
HMGB1 release, we examined the effects
of TLR4/RAGE deficiency on SAAinduced activation of these signaling molecules. Consistent with the capacity of
SAA in stimulating NLRP3 inflammasome activation (21,44), we observed that
SAA significantly upregulated PKR expression (Figures 4A, B) and induced the
phosphorylation of both PKR (Figure 4A)
and STAT1 (Figure 4C). However, the disruption of TLR4 led to impairment of
SAA-induced phosphorylation of PKR
(Figure 4B) and STAT1 (Figure 4C). Because it only partly reduced SAA-induced
PKR upregulation (Figure 4B), it is therefore plausible that another receptor(s) participates in SAA-induced PKR upregulation. Double deletion of both TLR4 and
RAGE significantly impaired SAAinduced PKR upregulation (Figure 4B),
suggesting similarly important roles of
these receptors in SAA-induced PKR expression and HMGB1 release.
To verify the role of PKR phosphorylation in SAA-induced HMGB1 release,
we examined the effects of two classes
of PKR kinase inhibitors on PKR phosphorylation and HMGB1 release. At the
concentrations that almost completely
abolished SAA-induced PKR phosphorylation, 2-AP and C16 also effectively
attenuated SAA-induced STAT1 phosphorylation (Figure 5A). However, at
the concentrations that dramatically
suppressed PKR and STAT1 phosphorylation, these PKR kinase inhibitors also
inhibited SAA-induced HMGB1 release
(Figure 5B), supporting an important
role for PKR phosphorylation in SAAinduced HMGB1 release.
Characterizing SAA-Neutralizing
Polyclonal Antibodies
SAA contains several distinct functional
domains respectively responsible for: (a)
binding to HDL (D1, residue 1–28) (45);
(b) inhibiting immune cell
adhesion (D2, residue 29–42); (c) as-yetundefined function (D3, residue 43–76);
(d) a protease cleavage site between
residues 76 and 77 (46); and (e) activating
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Figure 4. Divergent roles of TLR4 and RAGE receptors in SAA-induced expression and
phosphorylation of PKR and STAT1. Thioglycollate-elicited primary macrophages were isolated from wild-type or mutant mice deficient in TLR2, TLR4, TLR2/RAGE or TLR4/RAGE. After
stimulation with LPS, HMGB1 or huSAA for 16 h, the intracellular levels of total PKR (A, B),
phosphorylated PKR (A) or STAT1 (C) were determined by Western blotting analysis. The
disruption of TLR4 abolished SAA-induced PKR and STAT1 phosphorylation, but only partly
impaired SAA-induced PKR upregulation. The concurrent knockout of both TLR4 and
RAGE completely abrogated SAA-induced PKR upregulation. *P < 0.05 versus –SAA or –LPS
controls; #P < 0.05 versus WT + SAA.

T cells (D4, residue 77–104; Figure 6A).
Specifically, the D2 domain contains the
YIGSD laminin-related and RGN
fibronectin-related motifs that may be responsible for inhibiting T cell and platelet
adhesion to extracellular matrixes (47,48).
The cleavage between 76-77 residues
leads to the liberation of: 1) the 8.5-kDa
amyloid A (AA) that integrate into pathogenic amyloid aggregates; and 2) the
3.5-kDa fragment (D4) that may activate
CD4 T cells to produce proinflammatory
cytokines (for example, IFN-γ) (49). To understand the roles of SAA in lethal sepsis,
we generated human SAA-specific polyclonal antibodies in rabbits, and characterized their SAA-reacting and -neutralizing

properties. Consistent with recent findings that SAA autoantibodies were detected in both healthy individuals and patients with various autoimmune diseases
(50,51), we found that before immunization, all rabbits produced small amounts
of anti-SAA autoantibodies, which were
immunoreactive to human, and fortunately not to murine, SAAs (data not
shown). After repetitive immunizations,
the titers of anti-SAA IgGs were dramatically elevated in most rabbits (for example, R1 and R3), but remained extremely
low in others (for example, R2; Figure 6B).
Dot blotting analysis revealed that these
SAA-reacting IgGs recognized several
overlapping peptides (for example, P7, P8

Figure 5. Inhibition of PKR phosphorylation
partly impaired SAA-induced HMGB1 release. Thioglycollate-elicited peritoneal
macrophages were stimulated with crude
LPS or SAA for 16 h in the absence or presence of PKR kinase inhibitors (2-AP and
C16), and the cellular levels of phosphorylated PKR and STAT1 (A) and HMGB1 (B)
were determined by Western blotting
analysis. *P < 0.05 versus –SAA or –LPS controls; #P < 0.05 versus +SAA or +LPS.

and P18), that corresponded to the SAA
D1/2 and D4 domains (Figure 6C).
Notably, most SAA-reacting IgGs (R1 and
R3) efficiently impaired SAA-induced
HMGB1 release (Figure 6D), whereas
these neutralizing activities were impaired by a preincubation with excessive
amounts of cross-reacting peptide (for example, P8, Figure 6D), suggesting that the
neutralization depended on specific antigen interactions.
Roles of SAA in Animal Models of
Lethal Endotoxemia and Sepsis
Given the capacity of SAA in activating PKR and inducing NO and HMGB1
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Figure 6. Characterization of SAA-specific polyclonal antibodies. (A) Sequence of synthetic SAA peptides. The reported functional domains were marked. (B) Western blotting
assay of SAA immunoreactivities. Blood was collected from septic mice at 24 h after CLP,
and serum proteins (1.0 μL/lane) were resolved by SDS-PAGE and immunoblotted with
total IgGs isolated from serum of SAA-immunized rabbits (R1, R2, R3). (C) Dot blot epitope
mapping. Synthetic peptides (P4–P19) were sequentially dotted on nitrocellulose membranes, and each membrane was respectively immunoblotted with anti-SAA IgGs from
each rabbit. (D) Effect of anti-SAA IgGs on SAA-induced HMGB1 release. Macrophages
were stimulated with SAA in the absence or presence of different (R1, R2, R3) IgGs, and
HMGB1 release was assayed by Western blotting. In parallel experiments, anti-SAA IgGs
were premixed with excessive amounts of different peptides, and the SAA-neutralizing activities were assessed. References cited in (A): Ohta S, et al. (45); Lavie G, et al. (46); Preciado-Patt L, et al. (47); Urieli-Shoval S, et al. (48); Yavin EJ, et al. (49).

release, we sought to further understand
the role of SAA in lethal systemic inflammation by using recombinant SAA protein or SAA-neutralizing IgGs. In animal
models of lethal endotoxemia, concurrent administration with SAA dose dependently exacerbated LPS-induced animal lethality, significantly decreasing
animal survival rates from 90% to 60%
(Figure 7A). In contrast, repetitive administration of SAA-neutralizing IgGs
(at +0.5 and +24 h after LPS) conferred a

significant protection against lethal endotoxemia, increasing animal survival from
0% to 50–75% (Figure 7B). In a clinically
relevant animal model of CLP-induced
sepsis, repetitive administration of SAAneutralizing IgGs (at +6, 24 and 48 h
after CLP) significantly improved animal
survival rates (Figure 7C), even when the
first dose was given in a delayed fashion.
Collectively, these findings suggested a
pathogenic role for SAA in animal models of lethal endotoxemia and sepsis.
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Figure 7. Divergent effects of SAA and
SAA-neutralizing IgGs on lethal endotoxemia and sepsis. (A) SAA exacerbated LPSinduced animal lethality. Balb/C mice were
given LPS (5 mg/kg, i.p.) either alone or in
combination with SAA (0.9 or 2.8 mg/kg)
to determine their effects on animal survival
rates. *P < 0.05 versus saline (LPS alone) control. (B) SAA-specific IgGs protected mice
against lethal endotoxemia. Balb/C mice
were given LPS (15 mg/kg) in combination
with either control IgGs (50 mg/kg, R2) or
SAA-neutralizing IgGs (R1 and R3, 50 mg/kg)
at +0.5 and +24 h after LPS, and animal survival rates were monitored for <2 wks. *P <
0.05 versus control IgGs. (C) SAA-neutralizing
IgGs rescued mice from lethal sepsis. Balb/C
mice were subjected to sepsis by CLP and
irrelevant (“control,” 50 mg/kg) or SAA
peptide–specific IgGs (50 mg/kg, R1 or R3)
were given at +6, +24 and +48 h after CLP
surgery. Shown in the figure was a summary of two independent experiments
with similar results. *P < 0.05 versus control
IgGs.

RESEARCH ARTICLE

DISCUSSION
Despite high homology between
human SAA and SAA1, their capacities in
inducing HMGB1 release are dramatically
different. The infrequently expressed
SAA, unlike the most abundant SAA1,
significantly induced HMGB1 release in
TLR4/RAGE- and PKR-dependent mechanisms. These novel findings were consistent with several studies that echoed their
dramatic differences in stimulating other
cytokines/chemokines (22–25). Although
SAA contained minute amount of endotoxins, this trivial contamination was not
likely the underlying cause for SAAmediated HMGB1 release, because (a) Ultrapure LPS (free from bacterial proteins
and nucleic acids; catalog # tlrl-pelps,
InvivoGen) fails to trigger HMGB1 release
even when given up to 10 μg/mL (29,30);
(b) the similarly prepared SAA1 that contained comparable amounts of endotoxin
still failed to induce HMGB1 release; (c)
endotoxin-neutralizing agent (for example, polymyxin B) effectively abrogated
LPS-induced (0.5 μg/mL), but not SAAinduced (0.5 μg/mL), HMGB1 release;
and (d) the disruption of TLR4 receptor
impaired crude LPS-, but not SAAinduced, HMGB1 release. Finally, consistent with the capacity of HDL in capturing SAA (52) and blocking its chemokine
activities (53), we found that HDL (catalog no. L8039; Sigma-Aldrich) effectively
attenuated SAA-induced HMGB1 release
(data not shown), further supporting SAA
as an inducer of HMGB1 release.
SAA signals via a family of receptors
(for example, TLR2, TLR4 and/or RAGE)
to activate NLRP3 inflammasome (21,44)
and to induce various cytokines/
chemokines and NO (22–25). However,
the signaling pathways leading to different proinflammatory mediators appear
to be distinguishable. For instance, TLR4
is both necessary and sufficient for SAAinduced PKR and STAT1 phosphorylation and consequent NO production, reinforcing the critical role for PKR (54)
and STAT1 (55) phosphorylation in iNOS
upregulation (Figure 8). Notably, these
PKR/STAT1-activating properties are
shared by other key HMGB1 stimuli (for

example, IFN-γ and crude LPS)
(27,30,32,54,56–58). Although LPS may
not directly activate STAT1, it can trigger
indirect STAT1 activation through intermediate production of IFNs (55) that are
capable of inducing HMGB1 release
(27,28,59). It is presently not yet known
whether SAA activates PKR/STAT1 to
induce HMGB1 release directly by itself
or indirectly through inducing IFNs or
other intermediates. In contrast, both
TLR4 and RAGE are critically needed for
SAA-mediated PKR upregulation and
HMGB1 release, because double deletion
of TLR4 and RAGE resulted in a complete impairment of both processes, reinforcing a critical role for PKR in the regulation of HMGB1 release (Figure 8).
Both genetic and pharmacological approaches are routinely used to assess the
divergent roles of inflammatory mediators in sepsis. However, caution should be
exercised when using gene knockout approaches to evaluate the pathogenic roles
of any particular mediators that are still
critically needed for maintaining beneficial physiological functions. For instance,
despite the well-established pathogenic
role of HMGB1 in infection- and injuryelicited inflammatory diseases (60,61), the
disruption of HMGB1 expression adversely renders animals more susceptible
to infectious (62) or injurious insults
(63,64), reinforcing the dramatically distinct roles of HMGB1 in health and disease (65). Similarly, in an animal model of
dextran sodium sulfate (DSS)-induced colitis, SAA1/2 knockout mice appeared to
be more susceptible to colitis, possibly because the intestinal epithelia-derived
SAAs are still critically needed for bactericidal activities (34). Thus, we used pharmacological approaches to evaluate the
role of SAA in animal models of lethal
systemic inflammation. Consistent with
the notion that early PAMP-elicited early
inflammatory responses might still be
needed for the innate immunity against
infection (66), it was previously shown
that prophylactic treatment with two antiSAA IgGs (mc29 and mc4; 1:1, beginning
at 12 h before CLP) reduced animal survival rates from 60% to 20% (67). In the

Figure 8. Proposed model for a pathogenic
role of SAA in lethal sepsis. In a subset of
septic patients, SAA is excessively accumulated and activates both TLR4 and RAGE
signaling pathways that contribute to PKR
upregulation and phosphorylation. PKR
phosphorylation does not just enable STAT1
activation and the resultant iNOS expression and NO production. It is not yet known
if PKR regulates HMGB1 release possibly
through facilitating RIP3-dependent
necroptosis or caspase 1–dependent pyroptosis. The SAA-induced excessive release
of NO and HMGB1 may contribute to the
pathogenesis of lethal sepsis. Future studies
are needed to evaluate the influence of
SAA-neutralizing antibodies on systemic accumulation of NO or HMGB1 in animal
models of sepsis.

present study, we found that delayed and
repetitive administration of SAA-neutralizing polyclonal antibodies conferred significant protection against lethal sepsis,
suggesting a pathogenic role of SAA during a late stage of sepsis. Consistently,
after lethal endotoxemia (10 mg/kg),
SAA1/SAA2 knockout mice exhibited a
higher lethality (ratio of animal death:
KO/WT = 6/4) within 24 h, followed by a
lower mortality (KO/WT = 2/5) between
24 and 48 h, supporting a pathogenic role
of SAAs during a late stage of sepsis.
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In septic patients (68), multiple SAA
isoforms have been found including the
most abundant SAA1, as well as several
scarce variants such as SAA, SAA2α and
SAA2β. The SAA2s differ from each
other only at position 71 (H versus R),
but differ from SAA1 at seven to eight
other positions, indicating a possible
polymorphism (69). Indeed, the frequencies of the α and β alleles at the SAA2
locus varied among different populations
(for example, the Turkish versus the
Azerbaijan and Kazakh) (70). At present,
it is not yet known why human SAA was
only detected in a subset of septic patients. Although human SAA and SAA1
differ from each other only at position 60
(D versus N) and 71 (H versus R), it will
be important to investigate whether a
possible polymorphism is associated
with SAA and SAA1. This is important
because genetic polymorphisms of proinflammatory cytokines (for example,
TNF) can influence their circulating levels and consequently influence the outcomes of sepsis (71).
CONCLUSION
Here we provided some evidence to
support the possibility that SAA might
be expressed only in a subset of septic
patients. Unlike the most abundant
SAA1, SAA significantly upregulated
PKR and stimulated HMGB1 release in a
TLR4/RAGE-dependent fashion. Pharmacological inhibition of PKR phosphorylation inhibited SAA-induced HMGB1
release, supporting an important role of
PKR in SAA-induced HMGB1 release
and NO production. In animal models of
lethal endotoxemia and experimental
sepsis, recombinant SAA exacerbated
LPS-induced animal lethality, whereas
SAA-neutralizing IgGs significantly improved animal survival. Collectively,
these findings have suggested a possible
role of SAA as an important mediator
and potential therapeutic target for lethal
inflammatory diseases.
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